CBPD-268

CBPD-268 is a potent and orally active CBP/p300 PROTAC degrader with an DC50 value of ≤ 0.03 nM. CBPD-268 induces CBP/p300 degradation and inhibits cell growth. CBPD-268 shows antitumor activity. CBPD-268 has the potential for the research of AR-positive prostate cancer (Structure Note: Red, Androgen receptor degrader (HY-W248665A) ; Blue, CBP/p300 ligand (HY-161483) ; Black, Linker) [1].

Product Specifications

CAS Number

[2832961-58-5]

UNSPSC

12352005

Target

Histone Acetyltransferase; PROTACs

Type

Reference compound

Related Pathways

Epigenetics; PROTAC

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/cbpd-268.html

Purity

99.23

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC(N1CC2=C(CC1)N([C@@H]3CC[C@H](CC3)CN4CC(C=C(C(N(C5CCC(NC5=O)=O)C6=O)=O)C6=C7)=C7C4)N=C2N8CCCC9=C8C=C(C(F)F)C(C%10=CN(N=C%10)C)=C9)=O

Molecular Formula

C44H47F2N9O5

Molecular Weight

819.90

References & Citations

[1]Chen Z, et al. Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor Regression. J Med Chem. 2024 Apr 11;67 (7) :5275-5304.